Expert Opinion on Emerging Drugs

Papers
(The H4-Index of Expert Opinion on Emerging Drugs is 11. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-08-01 to 2025-08-01.)
ArticleCitations
Emerging drugs for hemophilia A: insights into phase II and III clinical trials27
Emerging immune tolerance therapies for neuromyelitis optica spectrum disorder23
Combined chemo-immunotherapy in advanced non-small cell lung cancer: feasible in the elderly?20
Emerging and traditional 5-α reductase inhibitors and androgen receptor antagonists for male androgenetic alopecia18
Emerging drugs for the treatment of postsurgical pain18
New drugs targeting calcitonin gene-related peptide for the management of migraines15
Emerging drugs for the treatment of acne: a review of phase 2 & 3 trials14
A review of phase II and III drugs for the treatment and management of endometriosis14
Evolving role of VIADISC for chronic low back and discogenic pain: a narrative review14
Emerging medicines to improve the basic defect in cystic fibrosis13
Existing and emerging therapies for the treatment of invasive candidiasis and candidemia12
How can we prevent diarrhea induced by systemic treatments in oncological patients? An evaluation of phase II trials11
Emerging injectable therapies for osteoarthritis11
0.043442010879517